Skip to main content

Table 5 Univariable and multivariable analysis of factors associated with survival in patients with HCC underwent TACE using Cox regression

From: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization

Univariate analysis

Multivariate analysis

Factors

HR

95%CI

p-value

Factors

HR

95%CI

p-value

Age

0.99

0.97–1.007

0.26

    

Sex (male)

1.24

0.99–1.56

0.07

    

MELD score

1.07

0.98–1.16

0.14

    

Within up-to-seven criteria

0.92

0.68–1.26

0.62

    

CTP B

1.17

0.69–1.99

0.57

    

AFP > 20 ng/mL

1.82

1.16–2.85

0.009*

AFP > 20 ng/mL

1.77

1.10–2.84

0.018*

Baseline EZ-ALBI

Grade 1

Grade 2

Grade 3

 

–

1.36–3.52

1.14–6.40

–

0.001*

0.023*

Baseline EZALBI

Grade 1

Grade 2

Grade 3

 

-

1.24–3.88

1.24–8.57

-

0.007*

0.016*

1 (ref)

2.19

2.71

1 (ref)

2.20

3.26

Worsening EZ-ALBI grade

0.94

0.60–1.46

0.77

    
  1. AFP Alpha fetoprotein, CI Confident interval, CTP Child-Turcotte-Pugh, EZ-ALBI Easy albumin-bilirubin, HR Hazard ratio, MELD Model for end-stage liver disease, ng/mL Nanogram per milliliter
  2. *Significant p-value is ≤ 0.05